Literature DB >> 33301050

KOR Control over Addiction Processing: An Exploration of the Mesolimbic Dopamine Pathway.

Paige M Estave1, Mary B Spodnick2, Anushree N Karkhanis3.   

Abstract

Drug addiction is a complex, persistent, and chronically relapsing neurological disorder exacerbated by acute and chronic stress. It is well known that the dynorphin/kappa opioid receptor (KOR) system regulates stress perception and responsivity, while the mesolimbic dopamine system plays a role in reward and reinforcement associated with alcohol and substance use disorders. Interestingly, the dopamine and dynorphin/KOR systems are highly integrated in mesolimbic areas, with KOR activation leading to inhibition of dopamine release, further altering the perception of reinforcing and aversive stimuli. Chronic or repeated exposure to stress or drugs potentiates KOR function ultimately contributing to a hypodopaminergic state. This hypodopaminergic state is one of the hallmarks of hyperkatifeia, defined as the hypersensitivity to emotional distress that is exacerbated during drug withdrawal and abstinence. The relationship between stress and drug addiction is bidirectional; repeated/chronic stress promotes pro-addictive behaviors, and repeated cycles of drug exposure and withdrawal, across various drug classes, produces stress. Neuroadaptations driven by this bidirectional relationship ultimately influence the perception of the reinforcing value of rewarding stimuli. In this chapter, we address the involvement of the dopamine and dynorphin/KOR systems and their interactions in shaping reinforcement value processing after drug and stress exposure, as well as a combinatorial impact of both drugs and stress.
© 2020. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  Alcohol use disorder; Dopamine; Dynorphins; Kappa opioid receptor; Nucleus accumbens; Substance use disorder

Mesh:

Substances:

Year:  2022        PMID: 33301050      PMCID: PMC8192597          DOI: 10.1007/164_2020_421

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  159 in total

1.  Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway.

Authors:  R Spanagel; A Herz; T S Shippenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

2.  Dynorphin-kappa opioid receptor activity in the central amygdala modulates binge-like alcohol drinking in mice.

Authors:  Rachel I Anderson; Marcelo F Lopez; William C Griffin; Harold L Haun; Daniel W Bloodgood; Dipanwita Pati; Kristen M Boyt; Thomas L Kash; Howard C Becker
Journal:  Neuropsychopharmacology       Date:  2018-12-11       Impact factor: 7.853

3.  Opioid receptor-mediated inhibition of dopamine and acetylcholine release from slices of rat nucleus accumbens, olfactory tubercle and frontal cortex.

Authors:  M H Heijna; M Padt; F Hogenboom; P S Portoghese; A H Mulder; A N Schoffelmeer
Journal:  Eur J Pharmacol       Date:  1990-06-08       Impact factor: 4.432

Review 4.  Dopaminergic cellular and circuit contributions to kappa opioid receptor mediated aversion.

Authors:  Elyssa B Margolis; Anushree N Karkhanis
Journal:  Neurochem Int       Date:  2019-07-10       Impact factor: 3.921

5.  Presynaptic inhibition of gamma-aminobutyric acid release in the bed nucleus of the stria terminalis by kappa opioid receptor signaling.

Authors:  Chia Li; Kristen E Pleil; Alice M Stamatakis; Steven Busan; Linh Vong; Bradford B Lowell; Garret D Stuber; Thomas L Kash
Journal:  Biol Psychiatry       Date:  2012-01-05       Impact factor: 13.382

6.  Evidence that the aversive effects of opioid antagonists and kappa-agonists are centrally mediated.

Authors:  R Bals-Kubik; A Herz; T S Shippenberg
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

7.  Kappa2 opioid receptors in limbic areas of the human brain are upregulated by cocaine in fatal overdose victims.

Authors:  J K Staley; R B Rothman; K C Rice; J Partilla; D C Mash
Journal:  J Neurosci       Date:  1997-11-01       Impact factor: 6.167

8.  'Binge' cocaine administration induces a sustained increase of prodynorphin mRNA in rat caudate-putamen.

Authors:  R Spangler; E M Unterwald; M J Kreek
Journal:  Brain Res Mol Brain Res       Date:  1993-09

9.  Acute 'binge' cocaine administration elevates dynorphin mRNA in the caudate putamen of C57BL/6J but not 129/J mice.

Authors:  Stefan D Schlussman; Yong Zhang; Vadim Yuferov; K Steven LaForge; Ann Ho; Mary Jeanne Kreek
Journal:  Brain Res       Date:  2003-06-06       Impact factor: 3.252

10.  Adolescent social isolation increases cocaine seeking in male and female mice.

Authors:  Anne Q Fosnocht; Kelsey E Lucerne; Alexandra S Ellis; Nicholas A Olimpo; Lisa A Briand
Journal:  Behav Brain Res       Date:  2018-10-05       Impact factor: 3.332

View more
  4 in total

Review 1.  An updated assessment of the translational promise of G-protein-biased kappa opioid receptor agonists to treat pain and other indications without debilitating adverse effects.

Authors:  Alexander R French; Richard M van Rijn
Journal:  Pharmacol Res       Date:  2022-01-29       Impact factor: 7.658

2.  Self-Administration of Entactogen Psychostimulants Dysregulates Gamma-Aminobutyric Acid (GABA) and Kappa Opioid Receptor Signaling in the Central Nucleus of the Amygdala of Female Wistar Rats.

Authors:  Sophia Khom; Jacques D Nguyen; Sophia A Vandewater; Yanabel Grant; Marisa Roberto; Michael A Taffe
Journal:  Front Behav Neurosci       Date:  2021-12-16       Impact factor: 3.617

3.  Distinct Role of Dopamine in the PFC and NAc During Exposure to Cocaine-Associated Cues.

Authors:  Yukie Kawahara; Yoshinori N Ohnishi; Yoko H Ohnishi; Hiroshi Kawahara; Akinori Nishi
Journal:  Int J Neuropsychopharmacol       Date:  2021-12-08       Impact factor: 5.176

Review 4.  Can pharmacotherapy improve treatment outcomes in people with co-occurring major depressive and cocaine use disorders?

Authors:  Gustavo A Angarita; Hasti Hadizadeh; Ignacio Cerdena; Marc N Potenza
Journal:  Expert Opin Pharmacother       Date:  2021-06-23       Impact factor: 4.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.